RDC 954/2024: ANVISA’s New Milestone for Simplified Drug Registration in Brazil

RDC 954/2024 represents a significant advance in the simplification and optimization of the drug registration process with ANVISA. The regulation establishes clear criteria for simplified registration, aiming for greater efficiency and agility for the regulated sector. The blog post will detail the key points of the RDC and the importance of ANVISA’s guidance for the correct application of the new rules, highlighting how GRP Brazil can help companies adapt to this new scenario.
The New Digital Frontier of Health: Understanding SaMD (Software as Medical Device) Regulation by ANVISA

The advance of technology has turned applications, platforms, and Artificial Intelligence (AI) into essential tools for diagnosis and treatment. ANVISA (Brazil’s National Health Surveillance Agency) is updating its rules to keep pace with this evolution. The focus is on RDC 657/2022, which establishes the foundation for the regulation of Software as a Medical Device (SaMD), ensuring that these digital innovations are safe and effective for the patient. The recent expansion of the target audience for the Agency’s inspection course reinforces its commitment to training and oversight in this sector.
ANVISA Reinforces Commitment to Drug Safety at International Pharmacovigilance Event

The Brazilian Health Regulatory Agency (ANVISA) recently participated in a major international event, where it reaffirmed its crucial role in monitoring drug safety. This blog details the main topics addressed by the Agency regarding Pharmacovigilance, the advancement in managing adverse events in Brazil, and the direct impact of these discussions on the operations and strategies of Regulatory Affairs companies in the sector.
ANVISA and the ICH: How Regulatory Harmonization Strengthens the Brazilian Pharmaceutical Sector

Brazil’s participation in the ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use) marks a strategic milestone for the national pharmaceutical industry. This Blog explains what the ICH is, the importance of ANVISA’s presence in this global forum, and how regulatory harmonization drives innovation and access to new treatments in the country.
Strengthening Health in Latin America: Brazil and Mexico Join Forces in Historic Agreements

In a strategic move to strengthen public health in Latin America, Brazil and Mexico are advancing negotiations to sign important bilateral agreements. Preliminary discussions, which took place in August, involved a Brazilian delegation led by Vice President Geraldo Alckmin and the Mexican government, led by President Claudia Sheinbaum. The main focus of these agreements is cooperation in key areas such as vaccines, medicines, and regulatory harmonization. The final agreements are expected to be signed in 2026.
Anvisa’s Regulatory Agenda and Strategic Plan

This Blog analyzes the importance of ANVISA’s 2024-2025 Regulatory Agenda and its 2024-2027 Strategic Plan for companies operating in regulatory affairs. The text explains how these documents serve as a planning guide, helping companies anticipate new regulations and align their strategies to ensure compliance and operational efficiency.
Brazil Approves New Composition for Seasonal Influenza Vaccines

Annual influenza vaccination is one of the most effective strategies for preventing respiratory complications and reducing hospitalizations caused by the flu virus. Each year, the vaccine composition must be updated based on the most recent circulating strains. In 2025, ANVISA approved a new regulation defining the composition of seasonal influenza vaccines to be used in Brazil, aligning the country with World Health Organization (WHO) recommendations.
The end of paper at Anvisa! Electronic Protocol is the future of Health Surveillance

The Brazilian Health Surveillance Agency (ANVISA) will fully adopt the electronic document protocol from March 13, 2025, as established by RDC 947/2024. This change will eliminate the need for paper documents, promoting greater agility in document analysis, modernizing processes and reducing operating costs, especially those related to digitization and physical storage.
IMDRF Releases Key Guidance Documents for Medical Device Software

The International Medical Device Regulators Forum (IMDRF) has released two key guidance documents to support the regulation of medical device software. These include Good Machine Learning Practice for Medical Device Development: Guiding Principles (IMDRF/AIML WG/N88 FINAL:2025) and Characterization Considerations for Medical Device Software and Software-Specific Risk (IMDRF/SaMD WG/N81 FINAL:2025). These documents aim to enhance global regulatory harmonization and assist medical device manufacturers in navigating compliance requirements for software-based and AI-driven technologies.
EMA Launches Early Scientific Advice Program for High-Risk Medical Devices

The European Medicines Agency (EMA) has launched a new Early Scientific Advice (ESA) program aimed at supporting the development of high-risk medical devices. This initiative seeks to provide manufacturers with timely regulatory guidance, ensuring that innovative medical technologies meet the necessary safety and efficacy standards before reaching the market.
Stakeholders Ask FDA to Harmonize Guidelines for Oligonucleotide-Based Therapies
The biopharmaceutical industry and other stakeholders are pressuring the US Food and Drug Administration (FDA) to harmonize its regulatory guidelines for oligonucleotide-based therapies. The request aims to eliminate discrepancies in the development, manufacturing and approval requirements for these innovative treatments, which have shown great potential in the fight against various genetic and infectious diseases.
ANVISA Publishes RDC 936/2024: New Guidelines for Health Products and Their Implications for Medicine

The National Health Surveillance Agency (ANVISA) has launched Collegiate Board Resolution (RDC) 936/2024, which establishes new guidelines for the regulation of health products. These changes aim to improve the safety and efficacy of products used in medicine, directly impacting health professionals and patients.